Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Aug 01, 2018 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results

Jun 26, 2018 7:30am EDT

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

Jun 20, 2018 4:01pm EDT

Rigel Announces Poster Presentations at FOCIS Annual Meeting

Jun 12, 2018 7:30am EDT

Rigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA

May 31, 2018 7:30am EDT

Rigel to Present at Jefferies 2018 Global Healthcare Conference

May 30, 2018 7:30am EDT

Rigel Appoints Dean Schorno as Chief Financial Officer

May 29, 2018 7:30am EDT

Rigel Announces Availability of TAVALISSEā„¢ (fostamatinib disodium hexahydrate) in the U.S.

May 01, 2018 4:01pm EDT

Rigel Announces First Quarter 2018 Financial Results and Provides Company Update

Apr 30, 2018 7:30am EDT

TAVALISSEā„¢ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo

Apr 24, 2018 7:30am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results

  • Previous
  • 1…
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • …42
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin